BioNexus Gene Lab Corp. - התחייבויות לטווח ארוך של החברה BGLC

The quotes provided below on the GURU.Markets platform illustrate the price action of BioNexus Gene Lab Corp. (BGLC), whose long-term debt stands at 0.00. The business relies on significant pricing power driven by unique mRNA analysis for early oncology detection. Innovative liquid biopsy methods render diagnostics preventive, while stability is ensured through the efficient operation of molecular laboratories and regular audits of reagent filling lines.

This indicator captures the total volume of credit obligations with a maturity of over one year, reflecting the capital financing strategy and the business's degree of reliance on debt capital. By analyzing the organization's long-term financial debt level, an investor can assess the ability of BioNexus Gene Lab Corp. (BGLC) to scale the production of "liquid biopsy" tests in Asia without a critical risk of insolvency.